Measurement and biological correlates of antibody bioactivity during antibody immunotherapies

Daniel Hagg, R. P. Junghans

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

An important factor in the effectiveness of antibody immunotherapies is the antibody bioactivity, or the availability of free binding sites. Bioactivity may be decreased in settings where the target antigen exists in a soluble form capable of binding to circulating antibody. Because many antigens have soluble forms, we developed a method for determining if antibody is bound by soluble antigen in vivo. As a model system, we studied the interaction of soluble interleukin-2 receptor alpha (Tac; IL2Rα; CD25) and anti-Tac antibody. We show first that HPLC readily separates free antibody from antibody which is monovalently or bivalently bound by soluble antigen. Further, we demonstrate that the distribution of the three forms of antibody accords with predictions of mass action and the binomial probability distribution. These methods were used to examine the bioactivity and concentration of free antibody in 14 patients undergoing therapeutic trial with Humanized anti-Tac antibody in leukemia and lymphoma. Results of two contrasting patients are highlighted. Low bioactivities correlated with reduced targeting of tumor cells and reduced therapeutic effectiveness. This report highlights the importance of soluble antigen in antibody therapies and demonstrates a simple method for evaluating in vivo bioactivity of antibody after therapeutic administration.

Original languageEnglish (US)
Pages (from-to)7-21
Number of pages15
JournalJournal of Immunological Methods
Volume219
Issue number1-2
DOIs
StatePublished - Oct 1 1998
Externally publishedYes

Fingerprint

Immunotherapy
Antibodies
Antigens
Anti-Idiotypic Antibodies
Interleukin-2 Receptor alpha Subunit
Binomial Distribution
Antibodies, Monoclonal, Humanized
Therapeutics
Lymphoma
Leukemia
Binding Sites
High Pressure Liquid Chromatography

Keywords

  • Antigen
  • Bioactivity
  • Humanized anti-Tac antibody

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Measurement and biological correlates of antibody bioactivity during antibody immunotherapies. / Hagg, Daniel; Junghans, R. P.

In: Journal of Immunological Methods, Vol. 219, No. 1-2, 01.10.1998, p. 7-21.

Research output: Contribution to journalArticle

@article{76fa386d1c0a4e8a9ff859119c06cdfe,
title = "Measurement and biological correlates of antibody bioactivity during antibody immunotherapies",
abstract = "An important factor in the effectiveness of antibody immunotherapies is the antibody bioactivity, or the availability of free binding sites. Bioactivity may be decreased in settings where the target antigen exists in a soluble form capable of binding to circulating antibody. Because many antigens have soluble forms, we developed a method for determining if antibody is bound by soluble antigen in vivo. As a model system, we studied the interaction of soluble interleukin-2 receptor alpha (Tac; IL2Rα; CD25) and anti-Tac antibody. We show first that HPLC readily separates free antibody from antibody which is monovalently or bivalently bound by soluble antigen. Further, we demonstrate that the distribution of the three forms of antibody accords with predictions of mass action and the binomial probability distribution. These methods were used to examine the bioactivity and concentration of free antibody in 14 patients undergoing therapeutic trial with Humanized anti-Tac antibody in leukemia and lymphoma. Results of two contrasting patients are highlighted. Low bioactivities correlated with reduced targeting of tumor cells and reduced therapeutic effectiveness. This report highlights the importance of soluble antigen in antibody therapies and demonstrates a simple method for evaluating in vivo bioactivity of antibody after therapeutic administration.",
keywords = "Antigen, Bioactivity, Humanized anti-Tac antibody",
author = "Daniel Hagg and Junghans, {R. P.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0022-1759(98)00096-9",
language = "English (US)",
volume = "219",
pages = "7--21",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Measurement and biological correlates of antibody bioactivity during antibody immunotherapies

AU - Hagg, Daniel

AU - Junghans, R. P.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - An important factor in the effectiveness of antibody immunotherapies is the antibody bioactivity, or the availability of free binding sites. Bioactivity may be decreased in settings where the target antigen exists in a soluble form capable of binding to circulating antibody. Because many antigens have soluble forms, we developed a method for determining if antibody is bound by soluble antigen in vivo. As a model system, we studied the interaction of soluble interleukin-2 receptor alpha (Tac; IL2Rα; CD25) and anti-Tac antibody. We show first that HPLC readily separates free antibody from antibody which is monovalently or bivalently bound by soluble antigen. Further, we demonstrate that the distribution of the three forms of antibody accords with predictions of mass action and the binomial probability distribution. These methods were used to examine the bioactivity and concentration of free antibody in 14 patients undergoing therapeutic trial with Humanized anti-Tac antibody in leukemia and lymphoma. Results of two contrasting patients are highlighted. Low bioactivities correlated with reduced targeting of tumor cells and reduced therapeutic effectiveness. This report highlights the importance of soluble antigen in antibody therapies and demonstrates a simple method for evaluating in vivo bioactivity of antibody after therapeutic administration.

AB - An important factor in the effectiveness of antibody immunotherapies is the antibody bioactivity, or the availability of free binding sites. Bioactivity may be decreased in settings where the target antigen exists in a soluble form capable of binding to circulating antibody. Because many antigens have soluble forms, we developed a method for determining if antibody is bound by soluble antigen in vivo. As a model system, we studied the interaction of soluble interleukin-2 receptor alpha (Tac; IL2Rα; CD25) and anti-Tac antibody. We show first that HPLC readily separates free antibody from antibody which is monovalently or bivalently bound by soluble antigen. Further, we demonstrate that the distribution of the three forms of antibody accords with predictions of mass action and the binomial probability distribution. These methods were used to examine the bioactivity and concentration of free antibody in 14 patients undergoing therapeutic trial with Humanized anti-Tac antibody in leukemia and lymphoma. Results of two contrasting patients are highlighted. Low bioactivities correlated with reduced targeting of tumor cells and reduced therapeutic effectiveness. This report highlights the importance of soluble antigen in antibody therapies and demonstrates a simple method for evaluating in vivo bioactivity of antibody after therapeutic administration.

KW - Antigen

KW - Bioactivity

KW - Humanized anti-Tac antibody

UR - http://www.scopus.com/inward/record.url?scp=0032191773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032191773&partnerID=8YFLogxK

U2 - 10.1016/S0022-1759(98)00096-9

DO - 10.1016/S0022-1759(98)00096-9

M3 - Article

C2 - 9831385

AN - SCOPUS:0032191773

VL - 219

SP - 7

EP - 21

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1-2

ER -